A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
Status:
Completed
Trial end date:
2018-12-21
Target enrollment:
Participant gender:
Summary
The primary objectives are to confirm that donepezil hydrochloride has superior efficacy
compared with placebo in improving cognitive function, as measured by Alzheimer's Disease
Assessment Scale-Cognitive subscale (ADAS-cog), and to demonstrate that donepezil
hydrochloride has superior efficacy compared with placebo in improving global function, as
measured by Clinician's Interview-Based Impression of Change-plus Caregiver Input
(CIBIC-plus), in patients with dementia associated with cerebrovascular disease (VaD).